Please login to the form below

Not currently logged in
Email:
Password:

Biogen-Samsung

This page shows the latest Biogen-Samsung news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate

Daily Brief: Biosimilars ready to pounce on Humira, Hong Kong could rival Nasdaq, Kymab's OX40 candidate

Amgen’s copy Amgevita and Samsung and Biogen’s Imraldi both gained full approval last year, while Sandoz (a Novartis division) has also just gained approval for its biosimilar, to be ... Amgen, Samsung/Biogen and Sandoz.

Latest news

  • Settlement clears path for Biogen, Samsung’s Humira biosimilar Settlement clears path for Biogen, Samsung’s Humira biosimilar

    Settlement clears path for Biogen, Samsung’ s Humira biosimilar. Agreement could see Europe access Imraldi as early as October this year. ... Biogen and partner Samsung Bioepis have agreed a deal that will allow their biosimilar version of AbbVie’s

  • First Herceptin biosimilar cleared in Europe First Herceptin biosimilar cleared in Europe

    Samsung Bioepis has claimed the distinction of getting the first biosimilar of Roche’s $6.8bn breast cancer blockbuster Herceptin in the EU. ... The South Korea-based joint venture between Samsung and Biogen says the new biosimilar, called Ontruzant,

  • Samsung deal with Takeda looks beyond biosimilars Samsung deal with Takeda looks beyond biosimilars

    Samsung deal with Takeda looks beyond biosimilars. The duo plan to develop “multiple novel biologic therapies”. ... hoped. For Samsung Bioepis - a joint venture between Samsung and Biogen set up five years ago - the deal takes it from the relatively

  • Biogen launches Remicade biosimilar in the UK Biogen launches Remicade biosimilar in the UK

    Biogen launches Remicade biosimilar in the UK. Flixabi provides another low-cost alternative to J&J’ s biggest-selling drug. ... Developed by Samsung Bioepis - a joint venture between Biogen and Samsung BioLogics - and marketed in the EU by Biogen,

  • Novartis gets FDA panel backing for biosimilar Enbrel Novartis gets FDA panel backing for biosimilar Enbrel

    Samsung Bioepis - a joint venture between South Korea's Samsung and Biogen - bagged EU approval for their Benepali biosimilar in January and has already launched it in several markets, while GP2015

More from news
Approximately 3 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    S Korea. Preclinical as of Dec 2012. Rituxan/Mabthera (Rituximab). SAIT101. Samsung Bioepis. ... This is because only larger entities like Samsung Bioepis and Hanwha Chemical have sufficient resources to absorb the financial risks of failed trials.

  • Pharma deals during February 2013 Pharma deals during February 2013

    This time Merck is not going it alone, but has announced a collaboration with Samsung Bioepis (the joint venture between Samsung and Biogen Idec set up in December 2011. ... Samsung Bioepis will be responsible for all the development work, whilst Merck

  • Pharma deals during July 2012 Pharma deals during July 2012

    Two weeks prior to the announcement of the collaboration between Amgen and Watson, Biogen Idec and Samsung Biologics announced the establishment of a $300m joint venture to develop and commercialise biosimilars. ... With these developments, there is the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics